What would be the treatment options for metastatic clear cell carcinoma of kidney who develops recurrent thrombosis despite therapeutic anticoagulant on cabozantinib in second line treatment after failing immunotherapy?
Answer from: Medical Oncologist at Academic Institution
Any TKI will potentially increase the risk of thrombosis, so this is a bit of a challenge for the patient. However, cabozantinib, based on personal experience, is more likely to cause this complication and other TKIs may be better in this regard. If you need to completely avoid TKIs, everolimus mono...
Sign in or Register to read more
Answer from: Medical Oncologist at Academic Institution
While thrombosis/thromboembolic events are considered a class effect amongst several VEGF/TKIs, and venous and/or arterial thromboembolic events have been seen in 2-5% of patients with most agents, there may be individual differences in pro-thrombotic effects of these agents. In view of recurrent th...